hsp90a.1 Antibody

What is HSP90AA1 and how does it differ from other HSP90 isoforms?

HSP90AA1 (also known as HSP90α) is the inducible cytosolic isoform of heat shock protein 90, which functions primarily as a molecular chaperone. It is distinct from other HSP90 family members including:

• HSP90AB1 (HSP90β): The constitutively expressed cytosolic form that shares approximately 90% sequence identity with HSP90α

• HSP90B1 (GRP94): The endoplasmic reticulum-localized form

• TRAP1: The mitochondrial form

HSP90AA1 exists predominantly as a homodimer, while HSP90AB1 exists mainly as a monomer . The inducible nature of HSP90α makes it particularly relevant for stress response studies and cancer research .

What applications are HSP90AA1 antibodies validated for in research settings?

HSP90AA1 antibodies have been validated for multiple applications with varying optimal dilutions:

Most antibodies detect HSP90α at approximately 90-96 kDa under reducing conditions in SDS-PAGE .

How should HSP90AA1 antibodies be stored and handled to maintain optimal activity?

For maximum stability and activity retention:

• Store lyophilized antibodies at -20°C until reconstitution

• After reconstitution, store at -20°C and prepare small aliquots to avoid repeated freeze-thaw cycles

• For reconstituted antibodies in glycerol-containing buffers (e.g., 50% glycerol), storage at -20°C is sufficient

• Spin tubes briefly before opening to recover any material adhering to caps

• Long-term storage beyond 6 months should be at -70°C for reconstituted antibodies without preservatives

How can I validate the specificity of an HSP90AA1 antibody in my experimental system?

A comprehensive validation approach includes:

• Knockout/knockdown validation: Use HSP90AA1 knockout cell lines (e.g., HSP90α knockout HEK293T) alongside parental cells to confirm antibody specificity. Western blot should show absence of the specific band (~90-96 kDa) in knockout cells while maintaining detection in parental lines .

• Isoform cross-reactivity testing: Test against recombinant HSP90α and HSP90β proteins to evaluate potential cross-reactivity. The ideal HSP90AA1-specific antibody should detect only HSP90α .

• Parallel detection with multiple antibodies: Use antibodies targeting different epitopes of HSP90AA1 to confirm consistent detection patterns.

• Loading controls: Include appropriate loading controls (e.g., GAPDH) to verify equal protein loading and correct interpretation .

What are the optimal conditions for detecting HSP90AA1 by Western blotting?

For optimal Western blot detection:

• Use freshly prepared cell lysates in RIPA or immunoblot buffer with protease inhibitors

• Load 20-50 μg of total protein per lane

• Run under reducing conditions using Immunoblot Buffer Group 1

• Transfer to PVDF membrane (recommended over nitrocellulose for HSP90 detection)

• Block with 5% non-fat milk or BSA in TBST

• Primary antibody dilution: 1:1000 (Cell Signaling) or 1:3000 (Agrisera)

• Secondary antibody: Use HRP-conjugated secondary antibodies specific to host species (e.g., Anti-Rabbit IgG for rabbit-derived primaries)

• Development: Enhanced chemiluminescence (ECL) provides sufficient sensitivity for endogenous detection

How should I design experiments to distinguish between HSP90α and HSP90β in complex samples?

To differentiate between these highly similar isoforms:

• Antibody selection: Use isoform-specific antibodies validated with recombinant proteins. For HSP90α, antibodies like AF7247 have demonstrated specificity through knockout validation .

• Electrophoretic separation: Utilize high-resolution SDS-PAGE (8-10% gels with extended run times) to maximize separation based on slight molecular weight differences.

• 2D electrophoresis: Combine isoelectric focusing with SDS-PAGE to separate based on both pI and molecular weight differences.

• RNA interference controls: Include samples with siRNA-mediated knockdown of HSP90AA1 or HSP90AB1 to confirm band identity.

• Mass spectrometry validation: For definitive identification, excise bands and perform LC-MS/MS analysis for isoform-specific peptide sequences .

How is HSP90AA1 involved in cancer progression and immune resistance mechanisms?

HSP90AA1 plays crucial roles in cancer progression through multiple mechanisms:

• Immune resistance: HSP90A is upregulated in immune-edited tumor cells (P3) that develop resistance to cytotoxic T lymphocytes (CTLs). Silencing HSP90AA1 re-sensitizes these cells to CTL-mediated killing .

• Multi-modal resistance: HSP90A contributes to resistance against chemotherapy (cisplatin) and radiotherapy. Knockdown of HSP90AA1 reverses these resistant phenotypes .

• Cancer stem cell properties: HSP90A is important for maintaining cancer stem cell-like properties, including sphere-forming capacity and tumor-initiating properties in vivo .

• NANOG-TCL1A-AKT pathway: HSP90A potentiates AKT activation through TCL1A stabilization. The NANOG-HSP90A-TCL1A-AKT axis appears central to multi-aggressive properties of immune-refractory tumors .

• Therapeutic target: HSP90A inhibition with compounds like AUY-922 can render tumors susceptible to immunotherapies including adoptive cell transfer and anti-PD-1 therapy .

What experimental approaches can detect extracellular versus intracellular HSP90AA1 in cancer research?

For differential detection of extracellular versus intracellular HSP90AA1:

• Cell fractionation protocols:

  • Intracellular: Standard cell lysis with detergent-based buffers

  • Extracellular: Collection of conditioned media followed by concentration through ultrafiltration

• In situ detection methods:

  • Immunofluorescence with non-permeabilized cells (extracellular)

  • Immunofluorescence with permeabilized cells (total HSP90AA1)

  • Flow cytometry with and without permeabilization

• Secretion studies:

  • Pulse-chase experiments with metabolic labeling

  • Brefeldin A treatment to block conventional secretion pathways

  • Exosome isolation and purification to study vesicular export

• In vivo approaches:

  • Microdialysis for extracellular fluid sampling

  • Proximity ligation assays for detecting protein interactions in tissue sections

How can HSP90AA1 antibodies be utilized to study stress response mechanisms across species?

HSP90AA1 is highly conserved across species, making it an excellent target for comparative stress biology:

• Cross-species validation: Many antibodies show cross-reactivity with HSP90α from multiple species. For example, antibodies like Agrisera's AS08 346 react with HSP90 from Arabidopsis thaliana, Brachypodium distachyon, Chlamydomonas sp., and various plant species .

• Experimental design for evolutionary studies:

  • Compare HSP90AA1 expression in equivalent tissues across evolutionary distances

  • Standardize stress conditions to enable valid cross-species comparisons

  • Use multiple antibodies targeting conserved epitopes

• Quantification approaches:

  • qPCR for transcript levels, coupled with Western blot for protein levels

  • Absolute quantification using recombinant HSP90α standards

  • Differential expression analysis under controlled stress conditions

• Conservation analysis:

  • HSP90 shares approximately 60% amino acid similarity between mammalian and yeast proteins

  • 78% similarity exists between mammalian and Drosophila HSP90 proteins

What are the common causes of inconsistent HSP90AA1 detection in Western blots?

How should researchers interpret changes in HSP90AA1 expression across different experimental contexts?

Proper interpretation of HSP90AA1 expression changes requires consideration of multiple factors:

• Baseline expression variability:

  • HSP90AA1 represents 1-2% of total cellular protein under non-stress conditions

  • Expression levels vary by cell/tissue type and should be normalized appropriately

• Stress response dynamics:

  • Acute vs. chronic stress elicits different HSP90AA1 expression patterns

  • Consider kinetics with appropriate time-course experiments

• Context-dependent regulation:

  • Cancer cells often show constitutively high HSP90AA1 expression

  • Immune challenge can induce HSP90AA1 differently than thermal stress

• Technical considerations:

  • Compare fold-changes rather than absolute values between experiments

  • Use appropriate housekeeping genes/proteins that remain stable under your experimental conditions

  • Consider transcript vs. protein level discrepancies, which may indicate post-transcriptional regulation

What methodological approaches can resolve contradictory findings when studying HSP90AA1 in different cellular compartments?

To address compartment-specific contradictions:

• Cellular fractionation validation:

  • Use multiple fractionation protocols and compare results

  • Include compartment-specific markers (e.g., GAPDH for cytosol, HDAC1 for nucleus)

  • Quantify cross-contamination between fractions

• Complementary microscopy approaches:

  • Combine confocal microscopy with super-resolution techniques

  • Use co-localization with organelle-specific markers

  • Implement live-cell imaging to track dynamic localization changes

• Proximity-based approaches:

  • Proximity ligation assay (PLA) to detect interactions in specific compartments

  • BioID or APEX2 proximity labeling to identify compartment-specific interaction partners

• Genetic approaches:

  • Create compartment-targeted HSP90AA1 constructs

  • Use CRISPR-Cas9 to tag endogenous protein

• Integrative data analysis:

  • Combine proteomic, transcriptomic, and imaging data

  • Use computational models to reconcile apparent contradictions

How can HSP90AA1 antibodies be utilized in studying extracellular vesicle (EV) biology in cancer research?

Extracellular HSP90AA1 is increasingly recognized as important in cancer progression:

• EV isolation and characterization:

  • Differential ultracentrifugation followed by Western blot for HSP90AA1

  • Size exclusion chromatography to separate EV populations

  • Antibody-based capture of HSP90AA1-positive EVs

• Functional studies:

  • Neutralization of extracellular HSP90AA1 using function-blocking antibodies

  • Comparison of HSP90AA1-positive vs. negative EV populations

  • Analysis of recipient cell responses to HSP90AA1-containing EVs

• Clinical correlation studies:

  • Quantification of HSP90AA1-positive EVs in patient biofluids

  • Correlation with treatment response and disease progression

  • Development of liquid biopsy approaches

• Methodological considerations:

  • Use both N-terminal and C-terminal targeting antibodies to detect potential fragments

  • Include detergent controls to distinguish membrane-bound vs. luminal HSP90AA1

  • Implement mass spectrometry validation of antibody-detected HSP90AA1 in EVs

What are the current technical limitations in studying HSP90AA1 post-translational modifications and how might they be overcome?

Current limitations and potential solutions include:

• Modification-specific antibody limitations:

  • Limited availability of site-specific PTM antibodies

  • Solution: Develop new antibodies targeting key modification sites; employ mass spectrometry-based approaches

• Dynamic nature of modifications:

  • Rapid turnover of phosphorylation, acetylation events

  • Solution: Use phosphatase/deacetylase inhibitors; employ pulse-chase labeling with modification-specific isotope tagging

• Low abundance of modified forms:

  • Modified subpopulations may represent small fractions of total HSP90AA1

  • Solution: Implement enrichment strategies (phosphopeptide enrichment, PTM-specific IP)

• Functional significance determination:

  • Correlative vs. causative role of specific modifications

  • Solution: Generate modification-mimetic and modification-resistant mutants; use targeted degradation of modified subpopulations

• Integration of multiple modifications:

  • Difficulty in analyzing combinatorial effects of multiple PTMs

  • Solution: Develop computational models; use proteoforms analysis by top-down proteomics

How might single-cell approaches enhance our understanding of HSP90AA1 heterogeneity in complex tissues?

Single-cell methods offer powerful insights into HSP90AA1 biology:

• Single-cell transcriptomics:

  • scRNA-seq to identify cell populations with differential HSP90AA1 expression

  • RNA velocity analysis to capture dynamic regulation during cellular transitions

  • Spatial transcriptomics to map expression in tissue context

• Single-cell proteomics:

  • Mass cytometry (CyTOF) with HSP90AA1 antibodies

  • Single-cell Western blotting to quantify protein levels

  • Imaging mass cytometry for spatial proteomic analysis

• Functional heterogeneity assessment:

  • Single-cell cloning followed by stress response characterization

  • Live-cell imaging with HSP90AA1 activity reporters

  • Correlating HSP90AA1 levels with client protein stability

• Technological considerations:

  • Antibody validation at single-cell resolution

  • Fixation and permeabilization optimization for retention of cytosolic proteins

  • Computational approaches for integrating multi-omic single-cell data

These advanced approaches can reveal cell-to-cell variability in HSP90AA1 expression and function that may be masked in bulk analysis, particularly important in heterogeneous systems like tumors and developing tissues.

Frequently Asked Questions (FAQs) for HSP90AA1 Antibody Researchers

What is HSP90AA1 and how does it differ from other HSP90 isoforms?

HSP90AA1 (also known as HSP90α) is the inducible cytosolic isoform of heat shock protein 90, which functions primarily as a molecular chaperone. It is distinct from other HSP90 family members including:

• HSP90AB1 (HSP90β): The constitutively expressed cytosolic form that shares approximately 90% sequence identity with HSP90α

• HSP90B1 (GRP94): The endoplasmic reticulum-localized form

• TRAP1: The mitochondrial form

HSP90AA1 exists predominantly as a homodimer, while HSP90AB1 exists mainly as a monomer . The inducible nature of HSP90α makes it particularly relevant for stress response studies and cancer research .

What applications are HSP90AA1 antibodies validated for in research settings?

HSP90AA1 antibodies have been validated for multiple applications with varying optimal dilutions:

Most antibodies detect HSP90α at approximately 90-96 kDa under reducing conditions in SDS-PAGE .

How should HSP90AA1 antibodies be stored and handled to maintain optimal activity?

For maximum stability and activity retention:

• Store lyophilized antibodies at -20°C until reconstitution

• After reconstitution, store at -20°C and prepare small aliquots to avoid repeated freeze-thaw cycles

• For reconstituted antibodies in glycerol-containing buffers (e.g., 50% glycerol), storage at -20°C is sufficient

• Spin tubes briefly before opening to recover any material adhering to caps

• Long-term storage beyond 6 months should be at -70°C for reconstituted antibodies without preservatives

How can I validate the specificity of an HSP90AA1 antibody in my experimental system?

A comprehensive validation approach includes:

• Knockout/knockdown validation: Use HSP90AA1 knockout cell lines (e.g., HSP90α knockout HEK293T) alongside parental cells to confirm antibody specificity. Western blot should show absence of the specific band (~90-96 kDa) in knockout cells while maintaining detection in parental lines .

• Isoform cross-reactivity testing: Test against recombinant HSP90α and HSP90β proteins to evaluate potential cross-reactivity. The ideal HSP90AA1-specific antibody should detect only HSP90α .

• Parallel detection with multiple antibodies: Use antibodies targeting different epitopes of HSP90AA1 to confirm consistent detection patterns.

• Loading controls: Include appropriate loading controls (e.g., GAPDH) to verify equal protein loading and correct interpretation .

What are the optimal conditions for detecting HSP90AA1 by Western blotting?

For optimal Western blot detection:

• Use freshly prepared cell lysates in RIPA or immunoblot buffer with protease inhibitors

• Load 20-50 μg of total protein per lane

• Run under reducing conditions using Immunoblot Buffer Group 1

• Transfer to PVDF membrane (recommended over nitrocellulose for HSP90 detection)

• Block with 5% non-fat milk or BSA in TBST

• Primary antibody dilution: 1:1000 (Cell Signaling) or 1:3000 (Agrisera)

• Secondary antibody: Use HRP-conjugated secondary antibodies specific to host species (e.g., Anti-Rabbit IgG for rabbit-derived primaries)

• Development: Enhanced chemiluminescence (ECL) provides sufficient sensitivity for endogenous detection

How should I design experiments to distinguish between HSP90α and HSP90β in complex samples?

To differentiate between these highly similar isoforms:

• Antibody selection: Use isoform-specific antibodies validated with recombinant proteins. For HSP90α, antibodies like AF7247 have demonstrated specificity through knockout validation .

• Electrophoretic separation: Utilize high-resolution SDS-PAGE (8-10% gels with extended run times) to maximize separation based on slight molecular weight differences.

• 2D electrophoresis: Combine isoelectric focusing with SDS-PAGE to separate based on both pI and molecular weight differences.

• RNA interference controls: Include samples with siRNA-mediated knockdown of HSP90AA1 or HSP90AB1 to confirm band identity.

• Mass spectrometry validation: For definitive identification, excise bands and perform LC-MS/MS analysis for isoform-specific peptide sequences .

How is HSP90AA1 involved in cancer progression and immune resistance mechanisms?

HSP90AA1 plays crucial roles in cancer progression through multiple mechanisms:

• Immune resistance: HSP90A is upregulated in immune-edited tumor cells (P3) that develop resistance to cytotoxic T lymphocytes (CTLs). Silencing HSP90AA1 re-sensitizes these cells to CTL-mediated killing .

• Multi-modal resistance: HSP90A contributes to resistance against chemotherapy (cisplatin) and radiotherapy. Knockdown of HSP90AA1 reverses these resistant phenotypes .

• Cancer stem cell properties: HSP90A is important for maintaining cancer stem cell-like properties, including sphere-forming capacity and tumor-initiating properties in vivo .

• NANOG-TCL1A-AKT pathway: HSP90A potentiates AKT activation through TCL1A stabilization. The NANOG-HSP90A-TCL1A-AKT axis appears central to multi-aggressive properties of immune-refractory tumors .

• Therapeutic target: HSP90A inhibition with compounds like AUY-922 can render tumors susceptible to immunotherapies including adoptive cell transfer and anti-PD-1 therapy .

What experimental approaches can detect extracellular versus intracellular HSP90AA1 in cancer research?

For differential detection of extracellular versus intracellular HSP90AA1:

• Cell fractionation protocols:

  • Intracellular: Standard cell lysis with detergent-based buffers

  • Extracellular: Collection of conditioned media followed by concentration through ultrafiltration

• In situ detection methods:

  • Immunofluorescence with non-permeabilized cells (extracellular)

  • Immunofluorescence with permeabilized cells (total HSP90AA1)

  • Flow cytometry with and without permeabilization

• Secretion studies:

  • Pulse-chase experiments with metabolic labeling

  • Brefeldin A treatment to block conventional secretion pathways

  • Exosome isolation and purification to study vesicular export

• In vivo approaches:

  • Microdialysis for extracellular fluid sampling

  • Proximity ligation assays for detecting protein interactions in tissue sections

How can HSP90AA1 antibodies be utilized to study stress response mechanisms across species?

HSP90AA1 is highly conserved across species, making it an excellent target for comparative stress biology:

• Cross-species validation: Many antibodies show cross-reactivity with HSP90α from multiple species. For example, antibodies like Agrisera's AS08 346 react with HSP90 from Arabidopsis thaliana, Brachypodium distachyon, Chlamydomonas sp., and various plant species .

• Experimental design for evolutionary studies:

  • Compare HSP90AA1 expression in equivalent tissues across evolutionary distances

  • Standardize stress conditions to enable valid cross-species comparisons

  • Use multiple antibodies targeting conserved epitopes

• Quantification approaches:

  • qPCR for transcript levels, coupled with Western blot for protein levels

  • Absolute quantification using recombinant HSP90α standards

  • Differential expression analysis under controlled stress conditions

• Conservation analysis:

  • HSP90 shares approximately 60% amino acid similarity between mammalian and yeast proteins

  • 78% similarity exists between mammalian and Drosophila HSP90 proteins

What are the common causes of inconsistent HSP90AA1 detection in Western blots?

How should researchers interpret changes in HSP90AA1 expression across different experimental contexts?

Proper interpretation of HSP90AA1 expression changes requires consideration of multiple factors:

• Baseline expression variability:

  • HSP90AA1 represents 1-2% of total cellular protein under non-stress conditions

  • Expression levels vary by cell/tissue type and should be normalized appropriately

• Stress response dynamics:

  • Acute vs. chronic stress elicits different HSP90AA1 expression patterns

  • Consider kinetics with appropriate time-course experiments

• Context-dependent regulation:

  • Cancer cells often show constitutively high HSP90AA1 expression

  • Immune challenge can induce HSP90AA1 differently than thermal stress

• Technical considerations:

  • Compare fold-changes rather than absolute values between experiments

  • Use appropriate housekeeping genes/proteins that remain stable under your experimental conditions

  • Consider transcript vs. protein level discrepancies, which may indicate post-transcriptional regulation

What methodological approaches can resolve contradictory findings when studying HSP90AA1 in different cellular compartments?

To address compartment-specific contradictions:

• Cellular fractionation validation:

  • Use multiple fractionation protocols and compare results

  • Include compartment-specific markers (e.g., GAPDH for cytosol, HDAC1 for nucleus)

  • Quantify cross-contamination between fractions

• Complementary microscopy approaches:

  • Combine confocal microscopy with super-resolution techniques

  • Use co-localization with organelle-specific markers

  • Implement live-cell imaging to track dynamic localization changes

• Proximity-based approaches:

  • Proximity ligation assay (PLA) to detect interactions in specific compartments

  • BioID or APEX2 proximity labeling to identify compartment-specific interaction partners

• Genetic approaches:

  • Create compartment-targeted HSP90AA1 constructs

  • Use CRISPR-Cas9 to tag endogenous protein

• Integrative data analysis:

  • Combine proteomic, transcriptomic, and imaging data

  • Use computational models to reconcile apparent contradictions

How can HSP90AA1 antibodies be utilized in studying extracellular vesicle (EV) biology in cancer research?

Extracellular HSP90AA1 is increasingly recognized as important in cancer progression:

• EV isolation and characterization:

  • Differential ultracentrifugation followed by Western blot for HSP90AA1

  • Size exclusion chromatography to separate EV populations

  • Antibody-based capture of HSP90AA1-positive EVs

• Functional studies:

  • Neutralization of extracellular HSP90AA1 using function-blocking antibodies

  • Comparison of HSP90AA1-positive vs. negative EV populations

  • Analysis of recipient cell responses to HSP90AA1-containing EVs

• Clinical correlation studies:

  • Quantification of HSP90AA1-positive EVs in patient biofluids

  • Correlation with treatment response and disease progression

  • Development of liquid biopsy approaches

• Methodological considerations:

  • Use both N-terminal and C-terminal targeting antibodies to detect potential fragments

  • Include detergent controls to distinguish membrane-bound vs. luminal HSP90AA1

  • Implement mass spectrometry validation of antibody-detected HSP90AA1 in EVs

What are the current technical limitations in studying HSP90AA1 post-translational modifications and how might they be overcome?

Current limitations and potential solutions include:

• Modification-specific antibody limitations:

  • Limited availability of site-specific PTM antibodies

  • Solution: Develop new antibodies targeting key modification sites; employ mass spectrometry-based approaches

• Dynamic nature of modifications:

  • Rapid turnover of phosphorylation, acetylation events

  • Solution: Use phosphatase/deacetylase inhibitors; employ pulse-chase labeling with modification-specific isotope tagging

• Low abundance of modified forms:

  • Modified subpopulations may represent small fractions of total HSP90AA1

  • Solution: Implement enrichment strategies (phosphopeptide enrichment, PTM-specific IP)

• Functional significance determination:

  • Correlative vs. causative role of specific modifications

  • Solution: Generate modification-mimetic and modification-resistant mutants; use targeted degradation of modified subpopulations

• Integration of multiple modifications:

  • Difficulty in analyzing combinatorial effects of multiple PTMs

  • Solution: Develop computational models; use proteoforms analysis by top-down proteomics

How might single-cell approaches enhance our understanding of HSP90AA1 heterogeneity in complex tissues?

Single-cell methods offer powerful insights into HSP90AA1 biology:

• Single-cell transcriptomics:

  • scRNA-seq to identify cell populations with differential HSP90AA1 expression

  • RNA velocity analysis to capture dynamic regulation during cellular transitions

  • Spatial transcriptomics to map expression in tissue context

• Single-cell proteomics:

  • Mass cytometry (CyTOF) with HSP90AA1 antibodies

  • Single-cell Western blotting to quantify protein levels

  • Imaging mass cytometry for spatial proteomic analysis

• Functional heterogeneity assessment:

  • Single-cell cloning followed by stress response characterization

  • Live-cell imaging with HSP90AA1 activity reporters

  • Correlating HSP90AA1 levels with client protein stability

• Technological considerations:

  • Antibody validation at single-cell resolution

  • Fixation and permeabilization optimization for retention of cytosolic proteins

  • Computational approaches for integrating multi-omic single-cell data